Details

Autor(en) / Beteiligte

• Slezak, Anna J.
• Mansurov, Aslan
• Raczy, Michal M.
• Chang, Kevin
• Alpar, Aaron T.
• Lauterbach, Abigail L.
• Wallace, Rachel P.
• Weathered, Rachel K.
• Medellin, Jorge E.G.
• Battistella, Claudia
• Gray, Laura T.
• Marchell, Tiffany M.
• Gomes, Suzana
• Swartz, Melody A.
• Hubbell, Jeffrey A.

Titel

Tumor Cell-Surface Binding of Immune Stimulating Polymeric Glyco-Adjuvant via Cysteine-Reactive Pyridyl Disulfide Promotes Antitumor Immunity

Ist Teil von

• ACS central science, 2022-10, Vol.8 (10), p.1435-1446

Ort / Verlag

United States: American Chemical Society

Erscheinungsjahr

2022

Quelle

Electronic Journals Library

Beschreibungen/Notizen

• Immune stimulating agents like Toll-like receptor 7 (TLR7) agonists induce potent antitumor immunity but are limited in their therapeutic window due to off-target immune activation. Here, we developed a polymeric delivery platform that binds excess unpaired cysteines on tumor cell surfaces and debris to adjuvant tumor neoantigens as an in situ vaccine. The metabolic and enzymatic dysregulation in the tumor microenvironment produces these exofacial free thiols, which can undergo efficient disulfide exchange with thiol-reactive pyridyl disulfide moieties upon intratumoral injection. These functional monomers are incorporated into a copolymer with pendant mannose groups and TLR7 agonists to target both antigen and adjuvant to antigen presenting cells. When tethered in the tumor, the polymeric glyco-adjuvant induces a robust antitumor response and prolongs survival of tumor-bearing mice, including in checkpoint-resistant B16F10 melanoma. The construct additionally reduces systemic toxicity associated with clinically relevant small molecule TLR7 agonists.